Table 1. Genotypic and phenotypic changes selected by serial passage of wild-type virus with GSK3532795.

Selection				Substitutions, %										EC50, μM (FC)
Virus*	P #	Days	Final Conc. (nM)	MA			CA				CA/SP1		Pr	GSK 3532795	NFV
				A	A	V	V	G	R	T	V	A	R
				118	119	159	218	221	286	332	362	364	41
				T	V	I	M	E	K	S	I	V	G
WT	0	-	0	-	-	-	-	-	-	-	-	-	-	0.002	0.004
	8	63	0	-	-	-	100	-	-	-	-	-	-	0.001 (<1)	0.002 (<1)
	8	97	256	60	-	-	100	-	-	100	100	-	100	0.257 (128)	0.001 (<1)
	8	83	256	-	-	-	-	100	-	-	-	100	-	2.3 (>1000)	0.002 (<1)
WT p12	0	-	0	-	-	-	-	-	-	-	-	-	-	nd	nd
	8	63	0	-	20	-	100	-	-	-	-	-	-	0.001 (<1)	0.002 (<1)
	8	70	256	-	-	-	100	-	-	-	10	100	-	0.43 (21)	0.001 (<1)
	8	70	256	-	-	20	100	-	40	-	20	90	-	0.88 (44)	0.002 (<1)

CA, capsid; EC50, 50% effective concentration; FC, fold change relative to starting virus; MA, matrix; nd, not done; NFV, nelfinavir; P#, passage number; Pr, protease; SP1, spacer peptide 1; WT, wild-type

*NL_4-3 Gag P373S reporter-free virus, without (WT) or with (WTp12) prior culture adaptation